ZYDUSLIFE - Zydus Lifesciences Limited Share Price

In the earnings call for Q4 FY26, management provided an optimistic outlook for FY27, projecting consolidated revenue growth in the high teens percentage. Specifically, they expect single-digit growth in the North American business and an outperformance in the Indian market by 200-400 basis points compared to current industry growth. International markets are anticipated to maintain robust momentum, continuing the 40% growth seen in FY26.

Key financial metrics include:

• Consolidated revenues for FY26 at Rs. 271.5 billion, up 17% year-on-year.
• EBITDA margins improved to 31.2%, with consolidated EBITDA at Rs. 84.8 billion, up 20% year-on-year.
• For Q4 FY26, revenues stood at Rs. 75.9 billion, a 16% year-on-year increase, and net profit reached Rs. 15.9 billion, rising by 15% year-on-year.

Management highlighted several strategic initiatives:

1. Expansion into the international consumer wellness sector through the acquisition of Comfort Click Limited.
2. Strengthening the medical devices segment by acquiring Amplitude Surgical, with strategic focus on cardiology and nephrology.
3. Continued digital transformation efforts to enhance operational efficiencies using AI and advanced analytics.
4. An expectation of steady earnings growth from the non-generic specialty portfolio and ongoing investments in rare disease treatments.

On margins, a slight decrease from FY26's levels was suggested, projecting EBITDA margins of over 24% for FY27, which factors in competition and operational costs. The management is comfortable with a net debt to EBITDA ratio of around 1x, underlining fiscal discipline during acquisition pursuits.

Overall, the tone was one of confident growth, focusing on sustained performance across core segments, while navigating the challenges posed by competitive and operational dynamics.

Question: "Kunal Dhamesha: FY26 has been exceptionally strong for us, where do you see FY27, from the growth perspective as well as the profitability perspective? Any outlook here would be helpful."

Answer: We are pleased with our FY26 performance and expect high teens growth for FY27 despite a high base from FY26. For North America, we anticipate single-digit growth, while in India, we expect to outperform the market by 200-400 basis points. Internationally, we expect strong momentum, continuing our double-digit growth. However, on margins, we expect them to be around 24% due to competition and expenses related to Saro's launch, considering around 8% in R&D expenses.

Question: "Kunal Dhamesha: Sharvil Bhai, on the specialty front, what would be the current contribution of this portfolio?"

Answer: Currently, our specialty portfolio, including Sentynl's three approved drugs, has broken even and is expected to become profitable soon. The 505(b)(2) segment is also scaling well with a broader oncology supportive care portfolio. We believe the specialty will drive significant growth, with Saro's commercialization beginning soon. We expect robust momentum for our non-generic specialty portfolio in the coming years.

Question: "Neha Manpuria: Can you talk about the confidence on maintaining outperformance in India? Where would you see more growth coming from?"

Answer: Our confidence stems from the strength of our innovative portfolio and recent traction in key therapies, particularly in chronic segments. Our focus on brand building and monetizing our biosimilars and new launches significantly contributes to our growth. We see sustained growth from our chronic portfolio and key therapy launches, reinforcing our belief in continued outperformance.

Question: "Harith Ahmed: Can you give us an update on Saroglitazar filing in PBC indication?"

Answer: The NDA for Saroglitazar in PBC has been filed, and we await acceptance from the FDA to provide a goal date. We are currently preparing commercialization strategies for the US, intending to launch independently and explore partnerships for European markets after securing approval.

Question: "Saion Mukherjee: Can you share the size of the biosimilar business today in India?"

Answer: Our biosimilar business has become a substantial contributor to our overall revenue in India, having crossed 800 crores. We expect it to scale further as we leverage partnerships and continue filing for new products, enhancing our presence in the market.

Question: "Nitin Agarwal: Should we expect a pickup more in the second half of the year for the US business?"

Answer: We expect some traction in the latter part of the fiscal year, although growth will be steady throughout the year without significant changes. Competition like that from Mira will pose challenges, but we remain optimistic regarding our overall growth trajectory.

Question: "Kunal Dhamesha: What is your plan from here regarding the $4,500 crore debt with the Assertio acquisition?"

Answer: We are comfortable with a net debt to EBITDA ratio of around one-time. We will continue pursuing bolt-on acquisitions focused on our specialty and 505(B)(2) franchise, indicating our confidence in cash flow and financial metrics to manage this level of debt effectively.

Question: "Surya Patra: What led to exceptional sequential growth in the US business despite not having Revlimid?"

Answer: The growth comes from multiple factors, including destocking at the quarter's end and strong volume growth across new products and our specialty portfolio. Our base business remains healthy, and we have seen increased shares for products launched in the last year, contributing positively.

Question: "Devang Sarawagi: What timeline can we expect for the Desidustat launch in China?"

Answer: We anticipate launching Desidustat in China in the second quarter of FY27. I will provide more details regarding readiness and commercial launch strategies as we progress with our partner.

This response contains key Q&A selections from the earnings call, highlighting the major themes and data without omitting important details or forward guidance.